Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia

NCT ID: NCT01865760

Last Updated: 2019-10-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-06-30
• Study Completion Date: 2016-03-31

Brief Summary

With increasing rates of obesity the number of anti-obesity operations performed is increasing; one of the most common is gastric bypass. Anti-obesity surgery ameliorates diabetes and several other serious comorbidities, but bariatric surgery is also associated with medical and nutritional complications.

Post-gastric bypass hyperinsulinemic hypoglycemia is a relative rare but serious complication often seen months to years after gastric bypass surgery. The patients experience neuroglycopenic symptoms (eg. inability to concentrate, weakness, altered mental status, loss of consciousness).

The purpose of this study is to determine whether glucagon-like peptide-1 (GLP-1)or other enteropancreatic factors (eg. gastric emptying rate) are responsible for the excessed insulin secretion seen in some patients after bariatric surgery.

Detailed Description

The increasing prevalence of obesity has led to parallel increase in bariatric surgery. Sustained weight reductions of up to 50 % of excess body weight are achieved in the majority of patients, and bariatric surgery is more effective in producing sustained weight loss. Another remarkable effect of bariatric surgery, especially Roux-en-Y gastric bypass (RYGB), is the profound and durable resolution of clinical manifestations of type 2 diabetes. Despite the favorable effects of bariatric surgery on obesity-associated morbidity and mortality, there has been mounting concerns about severe hypoglycemia associated with Roux-en-Y gastric bypass surgery.

This is an increasingly recognized condition characterized by neuroglycopenia and inappropriately elevated insulin concentrations. The patients experience autonomic symptoms with tremor, palpitation, sweating and hunger, and symptoms of neuroglycopenia such as inability to concentrate, weakness, drowsiness and behavioral changes. One issue complicating the characterization of post-gastric bypass surgery is that patients who have undergone bariatric surgery typically experience numerous post-prandial symptoms including the "dumping syndrome", which may be part of a continuum of post-gastric bypass hypoglycemia. We know that affected individuals have exaggerated insulin and glucagon-like peptide-1 response to meal consumption compared with asymptomatic individuals with prior gastric bypass surgery.

Ten patients with recurrent hypoglycemia events, including the presence of Whipple's triad, following gastric bypass surgery will participate in this study. Ten asymptomatic subjects with previous gastric bypass surgery and 10 control subjects with normal glucose tolerance and no prior gastrointestinal surgery will be recruited. Ten subjects with prior sleeve-gastrectomi will also participate in order to see if this operation is more beneficial in avoiding post-gastric bypass hypoglycemia.

Pre- and postprandial hormone levels and insulin secretion rates in response to 50 mg oral glucose tolerance test (OGTT), isoglycemic intravenous glucose infusion (IIGI) and 300 kcal liquid mixed meal will be measured in 3 different days separated by an interval of at least 1 week. These tests will be performed to see how the response to intravenous versus per oral glucose stimulation differ in the four different groups in regard to biomedical markers and symptoms of hypoglycemia.

All participants will wear Continuous Glucose Monitoring (CGM) for at least 5 days. During this period of time the subjects will be asked to come to the laboratory on two separate days to receive a high-carbohydrate meal and a low-carbohydrate meal respectively. The ingestion of the will be followed by three hours blood glucose measurements along with the CGM. The purpose of these test are to see the different response in glucose depending on the composition of the meal ingested, and to see whether CGM is reliably especially for measuring low levels of glucose.

The subjects with recurrent hypoglycemia events following gastric bypass surgery will receive the liquid mixed meal three times separated by at least one week; first as described earlier without receiving any drug and afterwards receiving either Exendin 9-39 (a specific GLP-1 receptor antagonist) or a Octreotid (Somatostatin analog). The purpose of these tests are to test the hypothesis that gastric bypass surgery associated hyperinsulinemic hypoglycemia is mediated by increased GLP-1 actions. Furthermore we use the somatostatin analog to test whether an inhibition of other gastroenteropancreatic hormones and a delay in gastric emptying of solids will change the glucose-insulin metabolism. To evaluate the impact of these pharmacologically interventions on gastric emptying rate we use acetaminophen absorption test.

Aim:

1. Is GLP-1 or other gastroenteropancreatic hormones pathophysiologically involved in the development of post-gastric bypass hyperinsulinemic hypoglycemia?

2. To investigate whether CGM can be used to diagnose hypoglycemia after gastric bypass surgery?

3. Which nutritional and pharmacological options do we have in managing the treatment of this condition?

Conditions

Obesity; Hypoglycemia; Surgery

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Gastric bypass surgery, hypoglycemia

Subjects with previous gastric bypass surgery (more then 1 year ago) and symptomatic hypoglycemia according to Whipples triade. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal. They will furthermore undergo two additional liquid mixed meal; one with concomitant treatment with synthetic Exendin 9-39 and another with treatment with Octreotide. All tests will be separated by at least one week.

Group Type: EXPERIMENTAL

Oral Glucose tolerance test (OGGT)

Intervention Type: DIETARY_SUPPLEMENT

At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes

Liquid mixed meal

Intervention Type: DIETARY_SUPPLEMENT

At baseline subject will consume the liquid mixed meal in 10 minutes

Octreotide

Intervention Type: DRUG

At baseline subjects will receive Octreotid 100 µg subcutaneous

Gastric bypass surgery, asymptomatic

Subjects with previous gastric bypass surgery (more then 1 year ago) without any signs of hypoglycemia. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.

Group Type: ACTIVE_COMPARATOR

Oral Glucose tolerance test (OGGT)

Intervention Type: DIETARY_SUPPLEMENT

At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes

Liquid mixed meal

Intervention Type: DIETARY_SUPPLEMENT

At baseline subject will consume the liquid mixed meal in 10 minutes

Controls

Healthy non-operated control subjects, matched on BMI, age and sex. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.

Group Type: OTHER

Oral Glucose tolerance test (OGGT)

Intervention Type: DIETARY_SUPPLEMENT

At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes

Liquid mixed meal

Intervention Type: DIETARY_SUPPLEMENT

At baseline subject will consume the liquid mixed meal in 10 minutes

Interventions

Oral Glucose tolerance test (OGGT)

At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes

Intervention Type: DIETARY_SUPPLEMENT

Liquid mixed meal

At baseline subject will consume the liquid mixed meal in 10 minutes

Intervention Type: DIETARY_SUPPLEMENT

Octreotide

At baseline subjects will receive Octreotid 100 µg subcutaneous

Intervention Type: DRUG

Other Intervention Names

Liquid mixed meal containing carbohydrate, fat and proteins; Somatostatin analogue

Eligibility Criteria

Inclusion Criteria

• Male/female
• Legally competent (habil)
• Age 20-65 years
• Speak and understand Danish
• Written consent
• Investigators verification of suitability

Exclusion Criteria

• Heart, liver or kidney disease
• Treatment with Cortisol
• Current treatment with antidiabetic medication
• Epilepsy
• Abuse/addiction to drugs

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Region MidtJylland Denmark

OTHER

Sponsor Role: collaborator

University of Aarhus

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bjørn Richelsen, Professor

Role: PRINCIPAL_INVESTIGATOR

The department of Endokrinology, Aarhus University Hospital

Locations

Department of Endocrinology, Aarhus University Hospital

Aarhus C, , Denmark

Countries

Denmark

Other Identifiers

1-16-02-138-13

Identifier Type: -

Identifier Source: org_study_id